Ö×ÁöÇÖ·¸,Neoplasm invasivenessÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ñ»·Ö×Áöϸ°û,Circulating tumor cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°ÚλÎó²î,setup errorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼äÖÊ»¯ÁÆ,interstitial chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖØ×éÃâÒß¶¾ËØ,Recombinant ImmunotoxinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
mdm2»ùÒò,mdm2 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÔʼÉñ¾ÍâÅß²ãÖ×Áö,Primitive neuroectodermal tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔ±íÐÍ,malignant phenotypeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
²îÒì¶È,difference degreeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Egr-1Æô¶¯×Ó,Egr-1 promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Á¬ÐøÄ£ÐÍ,continuous modelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÎÏÙ°©,lung adenocarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ªÒÆ°©,Metastatic carcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔ¼äÆ¤Áö,Malignant mesotheliomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸´Êý´Åµ¼ÂÊ,complex permeabilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
θ°©Ï¸°û,Gastric cancer cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÖÖÖ²,neoplasm seedingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼××´ÏÙת¼Òò×Ó-1,thyroid transcription factor-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Òò¹û·ÖÎö,causal analysisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
hTERTÆô¶¯×Ó,hTERT promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹Ç×ªÒÆÁö,bone metastasesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶àÔ·¢°©,Multiple Primary CarcinomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÒÊæ×¢ÉäÒº,Yanshu injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÂÁ¢ÐÔÏËάÐÔÖ×Áö,Solitary fibrous tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ß¼¶Ö¬·¾Ëá,higher fatty acidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Ç²ÎÊý»Ø¹é,Nonparametric regressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´×Ëá¼×µØÔÐͪ,megestrol acetateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÛ״ϸ°û°©¿¹Ô,Squamous cell carcinoma antigenÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖØ×éÈËÄÚÆ¤ÒÖËØ,Recombinant human endostatinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏúÊÛ½ð¶î,Consumption sumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÂÄÔÕÕÉä,Cranial irradiationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
B16ºÚÉ«ËØÁö,B16 melanomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼î»ùÇгýÐÞ¸´,Base excision repairÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÌÓÒÝ,Tumor escapeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
˳²¬/ͶҩºÍ¼ÁÁ¿,cisplatin/administration & dosageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏÆ¤ÑùѪ¹ÜÄÚÆ¤Áö,epithelioid hemangioendotheliomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈÏ֪ϵͳ,Cognitive systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐØÜÕËáºÏø,Thymidylate synthaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½ºÍÓÂÝ,Bulgaria inquinansÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄæÏò¼Æ»®,inverse planningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔÐİü»ýÒº,malignant pericardial effusionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
RNA¾ÛºÏø¢ò,RNA polymerase ¢òÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
DNAÍ»±ä,DNA mutationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿ÚÏãÌÇ,chewing gumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏÆ¤ÑùÈâÁö,Epithelioid sarcomaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ÷Ç¿·ÅÉäÖÎÁÆ,IMRTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ý¼ÌÐÔÃâÒßÖÎÁÆ,Adoptive immunotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿ÅÁ£Ï¸°ûÁö,Granular cell tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±´Ò¶Ë¹¶¨Àí,Bayes theoremÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏßÐÔÏìÓ¦,Linear responseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ßÇ¿¶È¾Û½¹³¬Éù(HIFU),high intensity focused ultrasound (HIFU)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ERCC1»ùÒò,ERCC1 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚÅßñ¼Áö,Endodermal sinus tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾ÄÚ·ÖÃÚÖ×Áö,Neuroendocrine tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
WWOX»ùÒò,WWOX geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑÎËáÅÁÂåŵ˾Çí,palonosetron hydrochlorideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éñ¾ÏµÍ³Ö×Áö,nervous system neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚÆ¤Éú³¤Òò×Ó/ÉúÎïºÏ³É,endothelial growth factors/biosynthesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÅàÃÀÇúÈû¶þÄÆ,Pemetrexed disodiumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ºÊÍ×÷ÓÃ,sustained releaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Í黯¼Á,Alkylating agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
̼·ÅÉäÐÔÍ¬Î»ËØ,Carbon radioisotopesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉúͪÒûʳ,Ketogenic dietÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö½þÈóÁܰÍϸ°û,tumor infiltrating lymphocytesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸´¶û¿µ×¢ÉäÒº,Fuerkang injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»¯ÁÆÄÍÒ©,ChemoresistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»¯ÁÆÏà¹ØÐÔ¸¹Ðº,chemotherapy-induced diarrheaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö¼ì²â,tumor detectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁܰÍÒýÁ÷,Lymphatic drainageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áö/ÖÐÒ©ÁÆ·¨,NEOPLASMS/TCD therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
E6µ°°×,E6 proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ¾úDNA,Bacterial DNAÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖØ×éÈËѪ¹ÜÄÚÆ¤ÒÖÖÆËØ/¶÷¶È,Recombinant human endostatin/EndostarÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ñ¡ÔñÔÔò,selection principleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
HedgehogÐźÅͨ·,hedgehog signaling pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÐÝÃß,Tumor dormancyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÎÁƼƻ®,treatment planningÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÒ׸ÐÐÔ,tumor susceptibilityÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹Ç»¯ÐÔÏËάÁö,Ossifying fibromaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
AskinÁö,Askin tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ôÊ»ùÌú·Û,carbonyl iron powderÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¦Â-éÏãÏ©ÑÜÉúÎï,¦Â-elemene derivativesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÑéÖ¤·½·¨,verification methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒþÐÎÄÉÃ×Á£,stealth nanoparticlesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ȱÑõ»·¾³,anoxic environmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒÖ°©»ùÒòp53,tumor suppressor gene p53Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ïνӵ°°×ÖÊÀà,Adaptor ProteinsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏÆ¤ÐÔÖ×Áö,Epithelial tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ùÖÊÖØËÜ,Matrix remodelingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô·¢Ôî,primary tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶¯Âö¹à×¢»¯ÁÆ,intra-arterial infusion chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁÙ´²Ö×Áöѧ,Clinical oncologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹Ñõ»¯·´Ó¦Ôª¼þ,antioxidant response elementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
WntÐźÅתµ¼Í¨Â·,Wnt signaling pathwayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈËÎÄ¿ÆÑ§,HumanitiesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÚÅß²ãñ¼Áö,endodermal sinus tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖØ×é¸Ä¹¹ÈËÖ×Áö»µËÀÒò×Ó,recombinant mutant human tumor necrosis factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÃÏ¢ÐÔÊÖÊõ,palliative operationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ùÖʽðÊôµ°°×ø-26,Matrix metalloproteinase-26Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Damiϸ°û,Dami cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|